BioCentury | Mar 23, 2017
Distillery Therapeutics

Cancer

...published online March 2, 2017 doi:10.1016/j.ccell.2017.02.002 CONTACT: Minh Diem Vu, EngMab AG, Pfaffikon, Switzerland email: dv@engmab.co Michael...
BioCentury | Dec 1, 2016
Clinical News

bluebird CAR T therapy leads to responses in MM study

...see BioCentury Extra, June 3, 2015) . In September, Celgene acquired another company targeting BCMA, EngMab AG...
BioCentury | Oct 10, 2016
Company News

EngMab, Celgene deal

...Celgene acquired EngMab for $600 million. Celgene said the acquisition will help it pursue tumor necrosis...
...17 ( BCMA ; TNFRSF17 ; CD269 ) as a target to treat multiple myeloma. EngMab...
...cells. EngMab’s EM801 , a T cell bispecific antibody targeting BCMA, has completed preclinical testing. EngMab AG...
BioCentury | Oct 3, 2016
Finance

ASH and others

...close, Celgene doubled down on BCMA by announcing plans to pay $600 million to acquire EngMab AG...
...N.J. Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR), Palo Alto, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. EngMab AG...
BioCentury | Sep 30, 2016
Company News

Celgene acquiring EngMab

...Celgene Corp. (NASDAQ:CELG) will acquire EngMab AG (Pfaeffikon, Switzerland) for $600 million. In a statement, Celgene said...
...17 ( BCMA ; TNFRSF17 ; CD269 ) as a target to treat multiple myeloma. EngMab...
Items per page:
1 - 5 of 5
BioCentury | Mar 23, 2017
Distillery Therapeutics

Cancer

...published online March 2, 2017 doi:10.1016/j.ccell.2017.02.002 CONTACT: Minh Diem Vu, EngMab AG, Pfaffikon, Switzerland email: dv@engmab.co Michael...
BioCentury | Dec 1, 2016
Clinical News

bluebird CAR T therapy leads to responses in MM study

...see BioCentury Extra, June 3, 2015) . In September, Celgene acquired another company targeting BCMA, EngMab AG...
BioCentury | Oct 10, 2016
Company News

EngMab, Celgene deal

...Celgene acquired EngMab for $600 million. Celgene said the acquisition will help it pursue tumor necrosis...
...17 ( BCMA ; TNFRSF17 ; CD269 ) as a target to treat multiple myeloma. EngMab...
...cells. EngMab’s EM801 , a T cell bispecific antibody targeting BCMA, has completed preclinical testing. EngMab AG...
BioCentury | Oct 3, 2016
Finance

ASH and others

...close, Celgene doubled down on BCMA by announcing plans to pay $600 million to acquire EngMab AG...
...N.J. Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR), Palo Alto, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. EngMab AG...
BioCentury | Sep 30, 2016
Company News

Celgene acquiring EngMab

...Celgene Corp. (NASDAQ:CELG) will acquire EngMab AG (Pfaeffikon, Switzerland) for $600 million. In a statement, Celgene said...
...17 ( BCMA ; TNFRSF17 ; CD269 ) as a target to treat multiple myeloma. EngMab...
Items per page:
1 - 5 of 5